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a b s t r a c t 
Background: Breakthrough infections after SARS-CoV-2 vaccination have been reported. Clinical outcomes 
in these persons are not widely known. 
Methods: We evaluated all vaccinated persons with breakthrough infection ≥14 days after the second 
vaccine dose and unvaccinated controls matched on age, sex, nationality, and reason for testing between 
December 23, 2020 and March 28, 2021 in Qatar. Our primary outcome was severe disease defined as 
hospitalization, mechanical ventilation, or death. 
Results: Among 456 persons cases of breakthrough infection and 456 unvaccinated matched controls with 
confirmed infection, median age was 45 years, 60.7% were males, and ≥1 comorbid condition was present 
in 61.2% of the vaccinated and 47.8% of the unvaccinated persons (P = 0.009). Severe disease was recorded 
in 48 (10.5%) of the vaccinated and 121 (26.5%) of the unvaccinated group (P < 0.001). Factors associated 
with severe disease included increasing age (HR vs. < 40 years old: > 40–60 years, HR 2.32; > 60–70 years, 
HR 4.34; > 70 years, HR 5.43); presence of symptoms at baseline (HR 2.42, 95%CI 1.44-4.07); and being 
unvaccinated (HR 2.84, 95%CI 1.80-4.47). 
Conclusions: In persons with breakthrough SARS-CoV-2 infection, increasing age is associated with a 
higher risk of severe disease or death, while vaccination is associated with a lower risk. Presence of 
comorbidities was not associated with severe disease or death among persons with breakthrough infec- 
tion. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 
This is an open access article under the CC BY-NC-ND license 
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201-9712/© 2021 The Authors. Published by Elsevier Ltd on behalf of International Socie
icense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Several highly efficacious vaccines against the SARS-CoV-2 in- 
ection are now available. In the real-world settings, the Pfizer- 
NT162b2 vaccine is approximately 90% effective in preventing 
ARS-CoV-2 infection and 94-100% effective in preventing severe 
r fatal disease.( Abu-Raddad et al., 2021 ; Dagan et al., 2021 ) Risk
f reinfection after natural infection is very low, with a reported 
revalence of approximately 0.18% in Qatar.( Abu-Raddad et al., 
020 ) More recently, breakthrough infections in fully vaccinated 
ersons have been reported though little is known about the risk 
actors, clinical presentation and outcomes for breakthrough infec- ty for Infectious Diseases. This is an open access article under the CC BY-NC-ND 

















































































































ions compared with demographically and clinically similar con- 
rols.( Butt et al., 2021 ; Hacisuleyman et al., 2021 ; Teran et al.,
021 ) Qatar was among the first nations to begin a national vac- 
ination campaign, with the first inoculation on December 23, 
020. Since then, over half the population in Qatar has received at 
east one dose of the vaccine and over one-third have been fully 
accinated. Vaccines used in Qatar include the Pfizer-BNT162b2 
nd the Moderna-mRNA-1273 vaccines, both of which require two 
oses 21 and 28 days apart respectively for optimal coverage. Af- 
er initial anecdotal reports of breakthrough infections among fully 
accinated persons, we sought to determine the risk factors and 
utcomes associated with breakthrough infections in the national 
OVID-19 database in Qatar. Our aim was not to determine vac- 
ine efficacy or effectiveness, which has already been reported by 
umerous groups. 
ethods 
tudy Population and Participants 
Qatar has created a national database of COVID-19 infected per- 
ons, which includes demographics, reason and results of SARS- 
oV-2 testing and vaccination related information. Among this na- 
ional database, we identified all persons who had received both 
oses of the Pfizer-BNT162b2 vaccine between December 23, 2020 
nd March 28, 2021, and who had a documented positive SARS- 
oV-2 PCR on a nasopharyngeal swab ≥14 days after the second 
ose of the vaccine. For each person thus identified with break- 
hrough infection, we identified a matched unvaccinated control 
ith confirmed infection, with matching done on age, sex, nation- 
lity, and reason for testing from the national database. Demo- 
raphic and clinical information was obtained through structured 
hart reviews of each case and control. 
efinitions 
Presence of SARS-CoV-2 infection was defined as a nasopharyn- 
eal swab positive by RT-PCR. Comorbidities were retrieved from 
ndividual chart review and recorded as being present based on at 
east one confirmatory physician note. Severe disease was defined 
s hospitalization, admission to an intensive care or monitored set- 
ing, invasive or non-invasive mechanical ventilation, or death. 
tatistical Analyses 
Baseline characteristics of persons with SARS-CoV-2 infection 
ith and without prior vaccination were compared using McNe- 
ar test for categorical and Mann–Whitney U test for continuous 
ariables. We determined the proportion of persons with severe 
nfection by various baseline characteristics. We used a Cox pro- 
ortional hazards model to calculate the hazard ratios and 95% 
onfidence intervals for factors associated with development of se- 
ere disease. Kaplan-Meier curves were constructed to determine 
he proportion of persons with event-free survival among the vac- 
inated and unvaccinated persons. 
esults 
Between December 23, 2020 and March 28, 2021, 449,222 per- 
ons in Qatar had received at least one dose of the SARS-CoV-2 
accine. During this time period, only the Pfizer-BNT162b2 vaccine 
as available in Qatar and 100% of the vaccinees received this vac- 
ine. We excluded those persons who had any positive PCR test 
or SARS-CoV-2 before and up to 14 days after the second vac- 
ine dose. Among those with at least 2 doses of the vaccine and 
o positive SARS-CoV-2 test up to 14 days after the second dose, 354 e identified 456 persons who had a confirmed SARS-CoV-2 PCR 
ositive test on a nasopharyngeal swab at least ≥14 days after the 
econd dose of the vaccine. We also identified 456 unvaccinated 
atched controls with confirmed infection as per the matching 
riteria described above. ( Figure 1 ) The median age in both groups 
as 45 years, 60.7% were males, and 31.6% were Qatari nationals. 
 Table 1 ) The most common reason for testing was clinical suspi- 
ion. At least one comorbid condition was present in 61.2% of the 
accinated and 47.8% of the unvaccinated persons (P = 0.009) with 
ypertension and diabetes being the most common comorbidities 
n both groups. ( Table 1 ) 
Severe disease was recorded in 48 persons (10.5%) among the 
accinated and 121 (26.5%) persons among the unvaccinated group 
P < 0.001). ( Table 2 ) The proportion of persons with severe disease
r death was significantly higher among unvaccinated persons in 
early every subgroup (except age ≤40 years or > 70 years where 
he number of persons in those groups was very small). Factors as- 
ociated with severe disease or death included increasing age (haz- 
rds ratios and 95% CI compared with those < 40 years old: > 40 –
0 years, HR 2.32, 95% CI 1.15-4.66; > 60 – 70 years, HR 4.34, 95% 
I 2.10-9.10; > 70 years, HR 5.43, 95% CI 2.20-13.53); presence of 
ymptoms at baseline (HR 2.42, 95% CI 1.44-4.07); and being un- 
accinated (HR 2.84, 95% CI 1.80-4.47). ( Table 3 ) Patient’s sex, na- 
ionality, body mass index, comorbidity count, reason for testing, 
nd cycle threshold value for PCR, an indicator of viral load, were 
ot associated with severe disease or death. 
In Kaplan-Meier survival analysis, unvaccinated persons had a 
ignificantly lower probability of being free of severe disease or 
eath over a 12 week follow up period (log-rank P-value < 0.0 0 01). 
 Figure 2 ) The difference in event-free survival was evident within 
he first two weeks and then plateaued, which reflects the out- 
ome definition (i.e. hospital or intensive care unit admission, me- 
hanical ventilation, or death). 
iscussion 
We provide the rates and risk factors for severe outcomes in 
ne of the largest cohorts of persons with breakthrough SARS-CoV- 
 infection after full vaccination and infection among matched un- 
accinated controls. 
Fully vaccinated persons who developed a breakthrough infec- 
ion were significantly less likely to experience severe disease or 
eath compared with matched unvaccinated persons who devel- 
ped infection. We found that the rate of severe disease or death 
mong the unvaccinated persons was nearly 3-fold higher than 
heir vaccinated counterparts. Most currently available vaccines 
onsistently provide > 90-100% primary protection against severe 
isease or death. Our data provides further assurances of the ef- 
ectiveness of the vaccines even when the vaccine was not able 
o prevent infection. These results are important since no SARS- 
oV-2 vaccine provides 100% protection against infection, and even 
ith ∼95% efficacy observed with the mRNA vaccines, a significant 
umber of breakthrough infections can be expected. Knowing that 
hese vaccines provide a high level of protection against severe dis- 
ase or death in case such breakthrough infection occurs, can boost 
he public’s confidence in vaccines and improve vaccination rates. 
Increasing age was strongly and independently associated with 
 higher risk of severe disease or death in persons with break- 
hrough infection. While this association has been well described 
n persons with primary infection,( Grasselli et al., 2020 ; Zhou et al., 
020 ) our results confirm that this association holds true in the 
opulation with breakthrough infection as well. It may be postu- 
ated that older persons have a higher burden of comorbidities that 
ay predispose them to poorer clinical outcomes. However, we 
ound an independent and “dose-dependent” association between 
ge (higher age groups with progressively higher hazards) and se- 
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Table 1 
Baseline characteristics of persons with documented SARS-CoV-2 infection after vaccination 
compared with infection in those who were not vaccinated. 
Vaccinated Unvaccinated P-value 
N = 456 N = 456 
Median age (IQR) years 45 (36, 59.8) 45 (36, 59.8) 1 
Male sex no. (%) 60.7% 60.7% 1 
Qatari/ Non-Qatari 31.6% 31.6% 1 
Median of average CT value (IQR) 24 (19, 30) 23 (18, 28) 0.001 
Symptomatic at baseline 52.6% 55.3% 0.02 
Reason for testing < 0.0001 
Clinical suspicion 45.6% 27.2% 
Surveillance 23.9% 21.9% 
Pre-travel requirement 2.9% 2.9% 
Contact tracing 9.6% 5.7% 
Individual request 5.9% 6.1% 
Port of entry testing 6.1% 6.1% 
Healthcare routine testing 5.3% 5.0% 
Other 0.7% 0.7% 
Missing 0.0% 24.3% 
Body mass index, kg/m 2 
Median (IQR) 29.4 (25.7, 33.1) 29.6 (25.6, 33.4) 0.7 
< = 30 183 125 0.75 
> 30 171 129 
Missing 102 202 
Comorbidity count < 0.0001 
None 38.8% 52.2% 
1-2 comorbidities 32.7% 30.9% 
3 or more comorbidities 28.5% 16.9% 
Comorbidities 
Diabetes 25.4% 23.7% 0.74 
Hypertension 30.7% 25.0% 0.088 
Coronary artery disease 11.8% 5.3% 0.001 
Chronic kidney disease 6.6% 2.9% 0.008 
Chronic lung disease 6.6% 5.0% 0.49 
Anemia 2.9% 2.9% 1 
Cancer diagnosis 3.3% 2.0% 0.31 
Stroke 0.4% 0.7% 1 
Immune diseases 4.4% 1.1% 0.007 
Hyperlipidemia / Dyslipidemia 16.9% 10.5% 0.009 
Hypothyroid 6.4% 5.7% 0.78 
Chronic liver disease 2.0% 2.0% 1 
Transplant 1.8% 0.9% 0.16 
Vitamin D deficiency 10.7% 7.7% 0.15 
Pregnancy 0.2% 1.3% 
Current smoker (if available) 9.9% 5.3% 0.01 
Table 2 
Disease severity (severe disease or death) rate per 1,0 0 0 person days by subgroups among those who were vacci- 
nated. 
Severe/ total Vaccinated N (%) Severe/ total Unvaccinated N (%) P-value ∗
Total number (48/456) 10.5% (121/456) 26.5% < 0.0 0 01 
By age 
< = 40 9/173 5.2% 16/173 9.2% 0.15 
> 40 – 60 13/185 7.0% 51/185 27.6% < 0.0001 
> 60 – 70 16/76 21.1% 42/76 55.3% < 0.0001 
> 70 10/22 45.5% 12/22 54.5% 0.55 
By nationality 
Qatari 14/144 9.7% 40/144 27.8% < 0.0001 
Non-Qatari 34/312 10.9% 81/312 26.0% < 0.0001 
By sex 
Male 28/277 10.1% 73/277 26.4% < 0.0001 
Female 20/179 11.2% 48/179 26.8% < 0.0001 
By BMI, kg/m 2 
< 30 13/183 7.1% 41/125 32.8% < 0.0001 
> = 30 19/171 11.1% 38/129 29.5% < 0.0001 
By co morbidities 
None 5/177 2.8% 37/238 15.5% < 0.0001 
1-2 13/149 8.7% 50/141 35.5% < 0.0001 
3 or more 30/130 23.1% 34/77 44.2% 0.002 
∗ Vaccinated vs. unvaccinated. 
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Figure 1. Construction of the study dataset. 
Table 3 
Factors associated with severe disease or death among persons with breakthrough infection 
and unvaccinated persons with infection. 
Hazards ratio (95% CI) P-value 
Unvaccinated (vs. vaccinated) 2.84 (1.80-4.47) < 0.0001 
Age (comparator: ≤40) 
40 – 60 2.32 (1.15-4.66) 0.02 
> 60 – 70 4.34 (2.10-9.10) < 0.0001 
> 70 5.43 (2.20-13.53) < 0.0001 
Male sex 1.11 (0.71-1.76) 0.64 
Qatari Nationality (comparator: Non-Qatari) 1.11 (0.69-1.73) 0.69 
Body mass index > = 30 kg/m 2 (comparator: < 30) 1.02 (0.66-1.59) 0.93 
Symptoms at baseline (comparator: no symptoms) 2.42 (1.44-4.07) 0.001 
Ct value (comparator > = 30) 
25 – 30 1.87 (0.92-3.77) 0.08 
20 – 24.99 1.28 (0.62-2.64) 0.5 
< 20 1.60 (0.80-3.19) 0.18 
Comorbidities (comparator: none) 
1-2 1.46 (0.80-2.66) 0.22 
3 or more 1.70 (0.87-3.13) 0.13 
Reason for testing (comparator: surveillance) 
Clinical suspicion 1.36(0.55-3.35) 0.5 
Contact tracing 1.64 (0.92-2.92) 0.09 
Port of entry testing 1.26 (0.61-2.62) 0.54 

















ere disease or death. Poor immune response in older age groups 
nd overall frailty may be potential explanations for a higher risk 
mong older persons. 
Burden of comorbidities was not associated with a higher risk 
f severe disease or death in our study. Comorbidities are well- 
ecognized risk factors for poorer clinical outcomes in patients 
ith SARS-CoV-2 infection.(Grasselli et al.; Wu et al. ) On the other 
and, symptomatic infection was associated with a higher risk. 
his is intuitive since those with symptoms are the ones who seek 356 edical care and meet the definition of clinical outcomes in our 
tudy. 
While there is no doubt that vaccination is among the most im- 
ortant and critical elements of the pandemic response, identifying 
actors associated with critical disease among those with break- 
hrough infection is of obvious clinical and policy significance. This 
nowledge can help the providers identify and prioritize the triage 
f those at highest risk and ensure appropriate monitoring. Policy- 
akers can also determine the resources required to provide the 
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ost effective and efficient services based on the population char- 
cteristics. 
The strengths of our study include a national population, appro- 
riately matched control group, excellent data collection and fol- 
ow up, and accurate characterization of the outcomes based on 
ndividual chart reviews. Limitations include relatively short follow 
p, and non-randomized protocols for treatment of SARS-CoV-2 in- 
ection. The latter is less relevant to our primary outcome of inter- 
st, since outcome for the majority (admission to the hospital) was 
etermined prior to when any treatment effects would have been 
pparent. It is possible that patients received some treatment prior 
o admission to the hospital, but we would expect that to be rela- 
ively similar in the case and control groups. 
In summary, increasing age is the most important factor deter- 
ining poor clinical outcomes in persons with breakthrough SARS- 
oV-2 infection, while vaccination is associated with a strong pro- 
ective effect. Older persons who develop breakthrough infection, 
articularly those with any symptoms, should be quickly evaluated 
nd monitored for severe outcomes. 
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